Lead: A team led by Laura Osanno published an analysis in Annals of Hematology examining the toxicity‑to‑efficacy ratio of venetoclax in hematologic malignancies, aiming to predict which patients are most likely to benefit without unacceptable adverse events. The study developed models that integrate clinical and laboratory predictors to stratify risk. Researchers correlated baseline factors with dose‑limiting toxicities and response outcomes, proposing predictive tools to inform dosing and monitoring strategies. The analysis covers real‑world cohorts and retrospective trial data to refine risk thresholds. Authors suggested the models could guide personalized venetoclax use, improve early toxicity mitigation, and serve as decision aids in designing combination regimens with overlapping myelosuppression risks.